Cargando…
Tumor Gene Expression Profiling in Women with Breast Cancer: Test Category: Prognostic
Differences in the expression of specific genes within breast tumors have been associated with risk of recurrence after treatment. Most women with Stage I or II node-negative breast cancer (especially when estrogen-receptor positive and treated with tamoxifen) remain disease-free at 10 years. Inform...
Autores principales: | Bellcross, Cecelia, W. David Dotson |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940139/ https://www.ncbi.nlm.nih.gov/pubmed/20877449 http://dx.doi.org/10.1371/currents.RRN1178 |
Ejemplares similares
-
Oncotype DX tumor gene expression profiling in stage II colon cancer: Application: Prognostic, risk prediction
por: Webber, Elizabeth M., et al.
Publicado: (2010) -
DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010) -
Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010) -
PLoS Currents: Evidence on Genomic Tests – At the Crossroads of Translation
por: Gwinn, Marta, et al.
Publicado: (2010) -
CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)